In addition,
Explicyte cure51 combine place exceptional:
Explicyte, a Bordeaux company of contract research (CRO) in precision oncology, has just established a strategic partnership with French Biotech Cure51, dedicated to understanding the biological mechanisms at work among the extraordinary survivors of cancer. However, This alliance aims to analyze tumor samples using single cell transcriptomic technologies. Furthermore, The gene expression cards thus obtained will be studied by the team of Data Science de Cure51. Therefore, in order to identify the molecular levers of long -term survival and to discover new therapeutic tracks.
Launched in November 2023. In addition, the Rosalind de Cure51 study aims to decipher the biological mechanisms of super-backing – These patients who challenge all forecasts by surviving explicyte cure51 combine place exceptional particularly aggressive cancers. Similarly, The study targets three cancers: lung cancer with small cells (coordinated by charity in Berlin). Similarly, glioblastoma (Center Léon Bérard, Lyon) and Metastatic pancreatic cancer (Gustave Roussy, Paris).
Cure51 has formed a single global network. Therefore, bringing together more than 100 cancer centers to collect tumor samples and clinical data from more than 1,000 patients from 40 countries. For example, The objective: to create an unprecedented multiomic database to bring out the processing of tomorrow. However, Thanks to the recognized expertise of explicyte in precision oncology. their perfect mastery of 10x Genomics spatial tools, Cure51 intends to accelerate its discoveries by deepening the understanding of the biology of exceptional survivors.
“At Cure51, we do reverse engineering to cure cancer. By combining technology. data and expertise in computational biology, we want to reveal the biological secrets of miraculous survivors to develop therapies that will make cancer manage explicyte cure51 combine place exceptional for all”, declare the co -founders of Cure51, Nicolas Wolikow and Simon Istolainen. “In just 18 months, we woven international partnerships giving us access to tumor samples and clinical data from“ outliers ”patients. To continue this dynamic. we are looking for a European partner capable of treating these precious samples with rigor and reproducibility. Expicyte has imposed itself as evidence, by its scientific excellence and its cutting -edge technology.
“In the past five years. the first spatial transcriptomic technologies have enabled us to make great advances in understanding the responses to immunotherapy, with more than 30 publications co-signed alongside our academic and industrial partners. In 2024, we crossed a CAP by deploying a unique spatial transcriptomic platform in Europe, based on technologies 10x geomics. Cohort of “outliers” patients of Cure51 is truly exceptional. adds Dr Alban Bessède, CEO of Explicyte.
In early 2025, Cure51 also announced a major partnership with Public Assistance-Paris Hospitals (AP-HP), the largest French hospital network. In March 2024, the company raised 15 million euros in priming, with the support of Sofinnova Partners, Hitachi Ventures and Lifex. The name of Cure51 pays tribute to Rosalind Franklin. pioneer in medical research, who, with his doctoral student Raymond Gosling, captured the famous “Photo 51” that made it possible to discover the DNA double propeller structure. The company’s motto: Cancer is destroyed (Cancer must be defeated).
For its part Explicyte is a Bordeaux company of research under contract specializing in precision oncology. founded in 2015 by immunologist Dr Alban Bessède. Based in the Cancer explicyte cure51 combine place exceptional Cancer Institute Bergonié Center in Bordeaux. the company brings together 25 scientists with complementary expertise (cell biology, digital pathology, medical oncology, data science) to support pharmaceutical and biotech laboratories in the discovery of therapies against solid tumors. Explicyte has co-signed more than 30 scientific publications on the mechanisms of response to immunotherapy over the past 5 years.
////////////////////////////////////////////////////////////////////////////////
The French Tech Bordeaux association relays the news of its members! Do you want to send us your latest important information? We can disseminate them to the community of innovation actors through our various communication channels: website, newsletters, social networks … Address us an email With a few lines and a photo. And not to miss anything, Register for our newsletter !
Is your business not yet a member of French Tech Bordeaux?
Join us here !
Explicyte cure51 combine place exceptional
Further reading: Why drink coffee could help you stay healthier, according to this study – Does the air conditioning make us sick? – Chum | Experimental treatments for patients short of options – These 3 types of nap increase the risk of mortality in seniors – This well -consumed food in summer is implicated in the most serious cases, alerts a doctor.
